Blauvelt A, Leonardi C, Elewski B, et al. - In this study, skin and nail clearance and patient‐reported outcomes for ixekizumab vs. guselkumab, up to Week 24 were compared. Researchers conducted statistical comparisons applying the Cochran‐Mantel‐Haenszel test stratified by the pooled site. They conducted time‐to‐first‐event comparisons applying Kaplan‐Meier analysis, and p values were generated applying the adjusted log‐rank test stratified by treatment group. In this study, 90% completed the trial (465/520 ixekizumab and 459/507 guselkumab) out of the 1,027 randomly assigned patients, At Week 24, Ixekizumab was non‐inferior to guselkumab incomplete skin clearance and superior in clearing nails. In patients with moderate‐to‐severe plaque psoriasis, Ixekizumab cleared skin more rapidly with a greater cumulative benefit, than guselkumab. For ixekizumab, safety findings were consistent with the known safety profile.